Skip to main content

LYVE-1 Antibody (ALY7) - BSA Free, Novus Biologicals

Bio-Techne includes Novus Biologicals | Catalog # NBP1-43411

Key Product Details

Species Reactivity

Validated:

Mouse

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG1 Clone # ALY7

Format

BSA Free

Concentration

0.5 mg/ml

Product Summary for LYVE-1 Antibody (ALY7) - BSA Free

Immunogen

This LYVE-1 Antibody (ALY7) was developed against mouse LYVE1.

Reactivity Notes

Use in Mouse reported in scientific literature (PMID: 33783987).

Marker

Lymphatic Vessel Marker

Clonality

Monoclonal

Host

Rat

Isotype

IgG1

Theoretical MW

35 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Scientific Data Images for LYVE-1 Antibody (ALY7) - BSA Free

Immunohistochemistry: LYVE-1 Antibody (ALY7) [NBP1-43411] - Immunohistochemistry of cryosections of mouse intestine at 2.5 ug/ml of anti-mouse LYVE-1 antibody followed by Anti-Rat IgG Rhodamine (right). Phase image of same field (left).
Flow Cytometry: LYVE-1 Antibody (ALY7) [NBP1-43411] - Analysis using the Biotin conjugate of NBP1-43411. Staining of LYVE-1 transfected cells with 0.06 ug of Rat IgG1 k Isotype Control Biotin (blue histogram) or 0.06 ug of Anti-Mouse Lyve-1 Biotin (purple histogram) followed by Streptavidin PE.
LYVE-1 Antibody (ALY7) - BSA Free

Western Blot: LYVE-1 Antibody (ALY7) - BSA Free [NBP1-43411] -

Glycolysis Regulates hESC Pluripotency and CTBP Expression by Regulating HIF-2 alpha under Hypoxic Conditions(A) Phase contrast images demonstrating the morphology of Hues-7 hESCs cultured at 5% oxygen in the presence or absence of 0.2, 1, or 10 mM 2-DG or 25 μM 3-BrP for 48 h. Scale bars, 200 μm.(B and C) Enzyme-linked assays were used to measure lactate production. Hues-7 hESCs were cultured with either 0, 0.2, 1, or 10 mM 2-DG (B) or in the presence or absence 3-BrP (C) for 48 h prior to collecting media samples for use in the enzyme-linked assays (n = 12–15 wells from at least 3 independent experiments).(D–F) qRT-PCR analysis of OCT4, SOX2, NANOG, LIN28B, and SALL4 (D), a panel of differentiation markers from the three developmental germ layers (E), and CTBP1 and CTBP2 (F) in Hues-7 hESCs treated with 10 mM 2-DG for 48 h compared with control cells (n = 3–5). See also Figure S3.(G–L) Quantification of OCT4, SOX2, NANOG, CTBP1, and CTBP2 expression using western blotting in Hues-7 (G–I) and Shef3 (J–L) hESCs treated with 10 mM 2-DG for 48 h compared with 0 mM 2-DG (n = 3 for Hues-7; n = 4 for Shef3).(M–O) Quantification of OCT4, SOX2, NANOG (M and N), CTBP1, and CTBP2 (M and O) expression using western blotting in Hues-7 hESCs cultured in the presence or absence of 25 μM 3-BrP for 48 h (n = 3–4).(P–S) Quantification of HIF-2 alpha expression using western blotting in Hues-7 (P and Q) and Shef3 (R and S) hESCs treated with or without 10 mM 2-DG for 48 h (n = 4 for Hues-7; n = 3 for Shef3). (T and U) Quantification of HIF-2 alpha expression using western blotting in Hues-7 hESCs cultured in the presence or absence of 25 μM 3-BrP for 48 h (n = 4).Bars represent mean ± SEM. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 significantly different to no treatment control; ns, no significant difference. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/30880076), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Applications for LYVE-1 Antibody (ALY7) - BSA Free

Application
Recommended Usage

Flow Cytometry

0.125 ug/10^6 cells in 100 uL

Immunocytochemistry/ Immunofluorescence

1:10 - 1:500

Immunohistochemistry

1:10 - 1:500

Immunohistochemistry-Frozen

2.5 ug/mL
Application Notes
This ALY7 antibody has been tested by flow cytometric analysis of transfected cell line or immunofluorescent microscopy of cryosections of mouse intestine. This can be used at less than or equal to 0.125 ug per million cells in a 100 uL total staining volume for flow cytometry and 2.5 ug/mL for immunofluorescent micoscopy. Use in Immunocytochemistry/Immunofluorescence was reported in scientific literature.
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Published Applications

Read 22 publications using NBP1-43411 in the following applications:

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

PBS (pH 7.2)

Format

BSA Free

Preservative

0.09% Sodium Azide

Concentration

0.5 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C. Do not freeze.

Background: LYVE-1

LYVE-1 (Lymphatic Vessel Endothelial Receptor 1) is a receptor for the extracellular matrix mucopolysaccharide hyaluronan (HA) and is primarily expressed by lymphatic endothelial cells in addition to the sinusoidal endothelium of the liver and spleen (1-3). HA, also called hyaluronic acid, is a main component of the extracellular matrix and functions largely in cell adhesion, migration, and tissue remodeling (2). HA undergoes a turnover process that involves release from the tissues to the afferent lymph, degradation within the lymph nodes, and removal of fragments by the liver (2,3). LYVE-1, in addition to other lymphatic proteins including VEGFR3, Prox1, and podoplanin, is a common marker for differentiating between the blood and lymphatic systems (2,3). Furthermore, LYVE-1 is closely related to the leukocyte receptor CD44, having ~44% sequence similarity (1-3). Like CD44, the LYVE-1 protein contains an extracellular HA-binding link domain, with N- and C-terminal extensions, located at the end of a glycosylated juxtamembrane domain stalk region, followed by a transmembrane region, and a cytoplasmic tail (1-3). The key features of the HA-binding like molecule are the three disulfide bridges formed by six cysteine residues (1-3). LYVE-1 is synthesized as a protein of 322 amino acids in length with a theoretical molecular weight of 35 kDa, although due to O-glycosylation often appears in SDS-PAGE at a molecular weight ranging from ~60-70 kDa (2,4). The role of HA-binding is further elucidated by the identification of LYVE-1 as a docking receptor for dendritic cells and macrophages, binding their surface HA to control the entry and migration into lymph vessels (1).

LYVE-1 has been an important marker in studies of embryonic and tumor lymphangiogenesis, as many cancers are characterized by early metastasis to the lymph nodes (1-3, 5). One study of five different vascular tumors in infants used immunohistochemical analysis and found positive LYVE-1 expression in infantile hemangioma, tufted angioma, and kaposiform hemangioendothelioma (5). LYVE-1 along with other markers such as GLUT-1, CD31, CD34, Prox-1, and WT-1 can be used to help provide immunohistologic profiles of various tumors and, when used in conjunction with clinical and histopathologic approaches, may offer better overall diagnosis and disease treatment (5).

References

1. Jackson D. G. (2019). Hyaluronan in the lymphatics: The key role of the hyaluronan receptor LYVE-1 in leucocyte trafficking. Matrix Biology : Journal of the International Society for Matrix Biology. https://doi.org/10.1016/j.matbio.2018.02.001

2. Jackson D. G. (2004). Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. https://doi.org/10.1111/j.1600-0463.2004.apm11207-0811.x

3. Jackson D. G. (2003). The lymphatics revisited: new perspectives from the hyaluronan receptor LYVE-1. Trends in Cardiovascular Medicine. https://doi.org/10.1016/s1050-1738(02)00189-5

4. Unitprot (Q9Y5Y7)

5. Johnson, E. F., Davis, D. M., Tollefson, M. M., Fritchie, K., & Gibson, L. E. (2018). Vascular Tumors in Infants: Case Report and Review of Clinical, Histopathologic, and Immunohistochemical Characteristics of Infantile Hemangioma, Pyogenic Granuloma, Noninvoluting Congenital Hemangioma, Tufted Angioma, and Kaposiform Hemangioendothelioma. The American Journal of Dermatopathology. https://doi.org/10.1097/DAD.0000000000000983

Long Name

Lymphatic Vessel Endothelial Hyaluronan Receptor 1

Alternate Names

LYVE1, XLKD1

Entrez Gene IDs

114332 (Mouse)

Gene Symbol

LYVE1

UniProt

Additional LYVE-1 Products

Product Documents for LYVE-1 Antibody (ALY7) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for LYVE-1 Antibody (ALY7) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...